In Times of Change, Insight Comes First

For investors looking to enter or expand in China’s healthcare, biotech, or pharmaceutical markets, these regulatory changes raise new red flags:

• Companies with hidden violations may lose access to public tenders

• M&A targets may suffer post-deal value erosion due to surprise enforcement

• Reputational risks can damage portfolio brand value globally

At Aegis Management, we specialize in conducting thorough pre-investment due diligence for foreign investors entering China’s complex regulated sectors—especially healthcare and pharma. Our services include:

• Deep-dive ESG and compliance audits

• Credit blacklist and regulatory penalty checks

• Litigation and license verification

• Reputation analysis of senior management

• Real-time policy risk alerts

We turn scattered public data and fragmented disclosures into actionable risk insights—helping you avoid high-risk targets and protect your investment.

Disclaimer: Certain images or references used in this article are sourced from publicly available materials. We respect intellectual property rights, and any rightful owner may contact us for content removal.（jielang.liu@aegismanage.com）